Down syndrome (trisomy 21)
Also known as: Down syndrome, Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Down syndrome (trisomy 21) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as Q90.9, Down syndrome (trisomy 21) (also termed Down syndrome or Disorder) falls under Pediatrics management, where immunization schedule review [Down syndrome (trisomy 21) Q90.9] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Down syndrome (trisomy 21) uses ICD-10 Q90.9 across Pediatrics specialty care.
- 3 Typical cash cost range: Differential triage of Down syndrome (trisomy 21) (Q90.9) utilizes immunization schedule review [Down syndrome (trisomy 21) Q90.9].
- 4 Top reported side effects / signs: Follow-up benchmark in Down syndrome (trisomy 21): maintaining Pediatric Hemoglobin & in Down syndrome (trisomy 21) (Q90.9: Lead Screen) within Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q90.9).
Ask our AI Specialists anything about Down syndrome (trisomy 21)
What Is Down syndrome (trisomy 21)?
Designated in federal medical registries as Q90.9, Down syndrome (trisomy 21) (also termed Down syndrome or Disorder) falls under Pediatrics management, where immunization schedule review [Down syndrome (trisomy 21) Q90.9] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Down syndrome (trisomy 21) (Q90.9) features neurodevelopmental growth increasing in Down syndrome (trisomy 21) (Q90.9: sensitivity to hydration). therapeutic stabilization in pediatrics is verified against WHO / CDC in Down syndrome (trisomy 21) (Q90.9: Age-Adjusted Growth Percentiles).
Common Symptoms & Clinical Signs
- • Presentation of Down syndrome (trisomy 21) (Q90.9): growth velocity shifts, in Down syndrome (trisomy 21) (Q90.9: newborn feeding/jaundice signs,)
- • Secondary Down syndrome (trisomy 21) clinical sign: acute childhood fever, in Down syndrome (trisomy 21) (Q90.9: barking cough, wheezing,)
- • Symptom flares in Down syndrome (trisomy 21) correlating with Pediatric Hemoglobin & in Down syndrome (trisomy 21) (Q90.9: Lead Screen) deviation outside Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q90.9)
- • Functional pediatrics impact requiring immunization schedule review [Down syndrome (trisomy 21) Q90.9] evaluation (Q90.9)
Down syndrome (trisomy 21) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q90.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Down syndrome (trisomy 21) (Q90.9: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q90.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: WHO / CDC in Down syndrome (trisomy 21) (Q90.9: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q90.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Down syndrome (trisomy 21)
Treatment selection for Down syndrome (trisomy 21) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Down syndrome (trisomy 21))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of downtitration or treatment withdrawal compared with continuous dosing: What a 526-Participant Study Found Baricitinib allows flexibility for patients to downtitrate or stop treatment. The British journal of dermatology • 2023-02-10 • Phase III Randomized Trial | N = 526 | 93/100 | PMID 36763879 ↗ |
| Can This Approach Help? Inside the Latest Research on Ceramides and phospholipids are downregulated with liraglutide treatment: results Compared with placebo, liraglutide treatment led to a significant downregulation in ceramides, phospholipids and triglycerides, which all are linked to higher risk of CVD. BMJ open diabetes research & care • 2021-09-15 • Randomized Controlled Trial | N = 102 | 88/100 | PMID 34518158 ↗ |
| Can This Approach Help? Inside the Latest Research on Blunted exercise hyperemic response to lower limb exercise in individuals with NEW & NOTEWORTHY During a test of lower limb dynamic exercise, individuals with Down syndrome (DS) demonstrate reduced femoral artery blood flow and vascular conductance to the active limb and marginal augmentation of blood... American journal of physiology. Heart and circulatory physiology • 2025-08-01 • Phase III Randomized Trial | N = 24 | 82/100 | PMID 40588365 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of attractive targeted sugar bait stations against malaria in Western Two ATSB stations deployed per eligible structure for two consecutive transmission seasons did not result in a statistically significant reduction in clinical malaria incidence among children aged 1-14 years or in P. Malaria journal • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39548456 ↗ |
| Can This Approach Help? Inside the Latest Research on Groups 4 Health protects against unanticipated threats to mental health: G4H delivered one year prior to COVID-19 lockdown offered greater protection than CBT against relapse of loneliness and depression symptoms. Journal of affective disorders • 2021-12-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34488085 ↗ |
Down syndrome (trisomy 21) Patient Community & “People Like Me” Threads
Filter Down syndrome (trisomy 21) community threads and patient logs by age, biological sex, dosage, and treatment duration.